MCID: HML002
MIFTS: 62

Hemolytic Anemia

Categories: Blood diseases, Rare diseases, Immune diseases, Genetic diseases, Metabolic diseases

Aliases & Classifications for Hemolytic Anemia

MalaCards integrated aliases for Hemolytic Anemia:

Name: Hemolytic Anemia 38 12 29 6 15 63
Anemia, Hemolytic 44 40 73
Anemia Hemolytic 12 55

Classifications:



External Ids:

Disease Ontology 12 DOID:583
ICD10 33 D55-D59
MeSH 44 D000743
NCIt 50 C34376
UMLS 73 C0002878

Summaries for Hemolytic Anemia

PubMed Health : 63 About hemolytic anemia: Hemolytic anemia (HEE-moh-lit-ick uh-NEE-me-uh) is a condition in which red blood cells are destroyed and removed from the bloodstream before their normal lifespan is over.Red blood cells are disc-shaped and look like doughnuts without holes in the center. These cells carry oxygen to your body. They also remove carbon dioxide (a waste product) from your body.Red blood cells are made in the bone marrow—a sponge-like tissue inside the bones. They live for about 120 days in the bloodstream and then die.White blood cells and platelets (PLATE-lets) also are made in the bone marrow. White blood cells help fight infections. Platelets stick together to seal small cuts or breaks on blood vessel walls and stop bleeding.When blood cells die, the body's bone marrow makes more blood cells to replace them. However, in hemolytic anemia, the bone marrow can't make red blood cells fast enough to meet the body's needs.Hemolytic anemia can lead to many health problems, such as fatigue (tiredness), pain, irregular heartbeats called arrhythmias (ah-RITH-me-ahs), an enlarged heart, and heart failure.

MalaCards based summary : Hemolytic Anemia, also known as anemia, hemolytic, is related to pyruvate kinase deficiency of red cells and congenital nonspherocytic hemolytic anemia, and has symptoms including icterus An important gene associated with Hemolytic Anemia is HBB (Hemoglobin Subunit Beta), and among its related pathways/superpathways are Metabolism and Glycosaminoglycan metabolism. The drugs Nitric Oxide and Peginterferon alfa-2a have been mentioned in the context of this disorder. Affiliated tissues include bone, heart and bone marrow, and related phenotypes are Decreased viability and Decreased viability

Wikipedia : 76 Hemolytic anemia or haemolytic anaemia is a form of anemia due to hemolysis, the abnormal breakdown of... more...

Related Diseases for Hemolytic Anemia

Diseases in the Hemolytic Anemia family:

Anemia, Autoimmune Hemolytic Congenital Hemolytic Anemia
Hemolytic Anemia Due to Erythrocyte Adenosine Deaminase Overproduction

Diseases related to Hemolytic Anemia via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 460)
# Related Disease Score Top Affiliating Genes
1 pyruvate kinase deficiency of red cells 34.5 G6PD PKLR
2 congenital nonspherocytic hemolytic anemia 34.5 G6PD GPI NT5C3A PKLR
3 congenital hemolytic anemia 33.6 ANK1 G6PD GPI HBA2 HBB PKLR
4 glutathione peroxidase deficiency 33.5 HBA2 HBB
5 hereditary spherocytosis 33.1 ANK1 EPB42 G6PD HBB PKLR SLC4A1
6 glucosephosphate dehydrogenase deficiency 33.1 G6PD HBB
7 glutathione synthetase deficiency 32.7 G6PD GSS
8 hemoglobin zurich 32.4 HBA2 HBB
9 heinz body anemias 32.4 HBA2 HBB
10 glucosephosphate isomerase deficiency 31.4 G6PD GPI
11 hereditary elliptocytosis 31.1 ANK1 SLC4A1 SPTB
12 beta-thalassemia 30.5 G6PD HBA2 HBB SPTB
13 sickle cell disease 30.3 G6PD HBA2 HBB
14 deficiency anemia 30.3 G6PD HBA2 HBB
15 alpha-thalassemia 30.3 G6PD HBA2 HBB
16 kernicterus 30.3 G6PD SLC4A1
17 malaria 30.2 ADAMTS13 G6PD HBA2 HBB PKLR SLC4A1
18 hemolytic anemia, nonspherocytic, due to hexokinase deficiency 12.5
19 warm antibody hemolytic anemia 12.4
20 uridine 5-prime monophosphate hydrolase deficiency, hemolytic anemia due to 12.4
21 gamma-glutamylcysteine synthetase deficiency, hemolytic anemia due to 12.4
22 renal tubular acidosis, distal, with hemolytic anemia 12.4
23 adenylate kinase deficiency, hemolytic anemia due to 12.4
24 drug-induced autoimmune hemolytic anemia 12.3
25 glutathione synthetase deficiency of erythrocytes, hemolytic anemia due to 12.3
26 hemolytic anemia, nonspherocytic, due to glucose phosphate isomerase deficiency 12.3
27 anemia, autoimmune hemolytic 12.3
28 hemolytic anemia, cd59-mediated, with or without immune-mediated polyneuropathy 12.3
29 mixed-type autoimmune hemolytic anemia 12.1
30 systemic lupus erythematosus with hemolytic anemia 1 12.1
31 autoimmune hemolytic anemia, warm type 12.1
32 hemolytic anemia, lethal congenital nonspherocytic, with genital and other abnormalities 12.1
33 glut1 deficiency syndrome 2 12.0
34 adenosine deaminase, elevated, hemolytic anemia due to 12.0
35 hemolytic anemia with thermal sensitivity of red cells 12.0
36 hemolytic anemia due to glutathione reductase deficiency 12.0
37 lymphopenic hypergammaglobulinemia, antibody deficiency, autoimmune hemolytic anemia, and glomerulonephritis 11.9
38 hemolytic anemia due to glyceraldehyde-3-phosphate dehydrogenase deficiency 11.9
39 neonatal autoimmune hemolytic anemia 11.9
40 autoimmune hemolytic anemia-autoimmune thrombocytopenia-primary immunodeficiency syndrome 11.9
41 hemolytic anemia due to erythrocyte adenosine deaminase overproduction 11.9
42 triosephosphate isomerase deficiency 11.9
43 thrombotic thrombocytopenic purpura, congenital 11.9
44 glucose phosphate isomerase deficiency 11.8
45 evans' syndrome 11.8
46 paroxysmal cold hemoglobinuria 11.8
47 hemolytic-uremic syndrome 11.8
48 cold agglutinin disease 11.8
49 anemia, nonspherocytic hemolytic, due to g6pd deficiency 11.7
50 rh-null, regulator type 11.7

Graphical network of the top 20 diseases related to Hemolytic Anemia:



Diseases related to Hemolytic Anemia

Symptoms & Phenotypes for Hemolytic Anemia

UMLS symptoms related to Hemolytic Anemia:


icterus

GenomeRNAi Phenotypes related to Hemolytic Anemia according to GeneCards Suite gene sharing:

26 (show all 11)
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased viability GR00107-A-1 10.33 AK1
2 Decreased viability GR00221-A-1 10.33 PKLR
3 Decreased viability GR00221-A-2 10.33 PKLR
4 Decreased viability GR00221-A-4 10.33 PKLR
5 Decreased viability GR00240-S-1 10.33 ALDOA CD59
6 Decreased viability GR00301-A 10.33 PKLR
7 Decreased viability GR00342-S-1 10.33 PGK1
8 Decreased viability GR00342-S-3 10.33 PGK1 PKLR
9 Decreased viability GR00402-S-2 10.33 NT5C3A PGK1 PIGA PKLR RHAG SLC4A1
10 no effect GR00402-S-1 9.62 GPI GSS HBA2 HBB HK1 NT5C3A
11 Increased simian virus 40 (SV40) infection GR00356-A-2 9.13 HK1 PGK1 PKLR

MGI Mouse Phenotypes related to Hemolytic Anemia:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 hematopoietic system MP:0005397 9.93 SPTB ADAMTS13 ANK1 CD59 EPB42 G6PD
2 homeostasis/metabolism MP:0005376 9.77 ADAMTS13 AK1 ANK1 CD59 EPB42 G6PD
3 mortality/aging MP:0010768 9.4 ADAMTS13 ANK1 CD59 G6PD GCLC GPI

Drugs & Therapeutics for Hemolytic Anemia

PubMedHealth treatment related to Hemolytic Anemia: 63

Treatments for hemolytic anemia include blood transfusions, medicines, plasmapheresis (PLAZ-meh-feh-RE-sis), surgery, blood and marrow stem cell transplants, and lifestyle changes.People who have mild hemolytic anemia may not need treatment, as long as the condition doesn't worsen. People who have severe hemolytic anemia usually need ongoing treatment. Severe hemolytic anemia can be fatal if it's not properly treated.

Drugs for Hemolytic Anemia (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 185)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Nitric Oxide Approved Phase 4 10102-43-9 145068 160954
2
Peginterferon alfa-2a Approved, Investigational Phase 4,Phase 2 198153-51-4 5360545
3
Ribavirin Approved Phase 4,Phase 3,Phase 2,Not Applicable 36791-04-5 37542
4
Epinephrine Approved, Vet_approved Phase 4 51-43-4 5816
5
Mannitol Approved, Investigational Phase 4 69-65-8 453 6251
6
Prilocaine Approved Phase 4 721-50-6 4906
7
Racepinephrine Approved Phase 4 329-65-7 838
8
Iron Approved Phase 4,Phase 2 7439-89-6 23925
9
Metformin Approved Phase 4 657-24-9 14219 4091
10
Desogestrel Approved Phase 4 54024-22-5 40973
11
Etonogestrel Approved, Investigational Phase 4 54048-10-1 40976 6917715
12 Antioxidants Phase 4,Phase 2
13
Bilirubin Phase 4 635-65-4 5280352
14 Pharmaceutical Solutions Phase 4,Phase 3,Phase 1
15 Protective Agents Phase 4,Phase 3,Phase 2,Not Applicable
16 Anti-Infective Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
17 Antimetabolites Phase 4,Phase 3,Phase 2,Not Applicable
18 Hormone Antagonists Phase 4,Phase 3,Phase 2,Not Applicable
19 Hormones Phase 4,Phase 3,Phase 2,Not Applicable
20 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 4,Phase 3,Phase 2,Not Applicable
21 Antiviral Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
22 Interferon-alpha Phase 4,Phase 3,Phase 2
23 interferons Phase 4,Phase 3,Phase 2,Not Applicable
24 diuretics Phase 4
25 Epinephryl borate Phase 4
26 Natriuretic Agents Phase 4
27 Liver Extracts Phase 4,Phase 3,Phase 2
28 Iron Chelating Agents Phase 4,Phase 2
29 Hypoglycemic Agents Phase 4
30 Contraceptive Agents Phase 4
31 Contraceptives, Oral Phase 4
32
Ethylene Phase 4 74-85-1 6325
33 Progestins Phase 4
34
Methylprednisolone Approved, Vet_approved Phase 3,Phase 2,Not Applicable 83-43-2 6741
35
Prednisolone Approved, Vet_approved Phase 3,Phase 2,Not Applicable 50-24-8 5755
36
Cyclophosphamide Approved, Investigational Phase 3,Phase 2,Phase 1,Not Applicable 50-18-0, 6055-19-2 2907
37
Miconazole Approved, Investigational, Vet_approved Phase 3,Phase 2,Phase 1,Not Applicable 22916-47-8 4189
38
Prednisone Approved, Vet_approved Phase 3,Phase 2,Not Applicable 53-03-2 5865
39
rituximab Approved Phase 3,Phase 2 174722-31-7 10201696
40
Primaquine Approved Phase 3 90-34-6 4908
41
Fludarabine Approved Phase 3,Phase 2 21679-14-1, 75607-67-9 30751
42
Vidarabine Approved, Investigational Phase 3,Phase 2 24356-66-9 32326 21704
43
Artemether Approved Phase 3 71963-77-4 119380 68911
44
Dapsone Approved, Investigational Phase 3 80-08-0 2955
45
Lumefantrine Approved Phase 3 82186-77-4 6437380
46
Proguanil Approved Phase 3 500-92-5 4923
47
Chlorambucil Approved Phase 3,Phase 2 305-03-3 2708
48
belimumab Approved Phase 3 356547-88-1 5957 10451420
49
Folic Acid Approved, Nutraceutical, Vet_approved Phase 3 59-30-3 6037
50
leucovorin Approved, Nutraceutical Phase 3 58-05-9 143 6006

Interventional clinical trials:

(show top 50) (show all 104)
# Name Status NCT ID Phase Drugs
1 Efficacy of Yinzhihuang Oral Liquid on Indirect Bilirubin of Neonates With Glucose-6-phosphate Dehydrogenase Deficiency Unknown status NCT02594904 Phase 4 Yinzhihuang Oral Liquid
2 Retreatment of Dialysis Patients With Chronic Hepatitis C With Pegylated Interferon Alfa-2a Plus Low Dose Ribavirin Completed NCT00491179 Phase 4 Pegylated interferon alfa-2a and ribavirin;Pegylated interferon alfa-2a and ribavirin
3 Pegylated Interferon Alfa-2a Plus Low Dose Ribavirin for Treatment-Naïve Hemodialysis Patients With Chronic Hepatitis C Completed NCT00491244 Phase 4 Peginterferon alfa-2a and ribavirin;Peginterferon alfa-2a
4 A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) Plus COPEGUS (Ribavirin) in Patients With Chronic Hepatitis C (CHC) Genotype 1 and Human Immunodeficiency Virus-1 (HIV-1) Co-infection Completed NCT00353418 Phase 4 Peginterferon alfa-2a;Ribavirin;Ribavirin
5 Evaluation of Ureteral Patency in the Post-indigo Carmine Era Completed NCT02677623 Phase 4 Pyridium;Sodium Fluorescein;Mannitol
6 Low-Dose Peginterferon and Ribavirin to Treat Chronic Hepatitis C in Patients Infected With HCV Genotype 2 or 3 Completed NCT00056862 Phase 4 Peginterferon alfa-2a;Peginterferon alfa-2a;Ribavirin
7 Pegylated Interferon and Ribavirin to Treat Chronic Hepatitis C With and Without Kidney Disease Completed NCT00028093 Phase 4 Peginterferon alfa-2a with Ribavirin;Peginterferon alfa-2a
8 Long-Term Therapy With Ribavirin for Chronic Hepatitis C Completed NCT00001854 Phase 4 Ribavirin
9 The Potential Hepatoprotective Effect of Metformin in Patients With Beta Thalassemia Major Recruiting NCT02984475 Phase 4 Metformin
10 Contraception in Women With Sickle Cell Disease Active, not recruiting NCT02594462 Phase 4 etonogestrel-releasing implant contraceptive
11 Rituximab in Auto-Immune Hemolytic Anemia Completed NCT01181154 Phase 3 rituximab (Mabthera®);Placebo
12 Prednisolone +/- Addition of Anti-CD20 Antibody, Rituximab, in Patients With Immune Hemolytic Anemia Completed NCT01134432 Phase 3 prednisolone + mabthera;Prednisolone
13 Combination Drug Therapy for Patients With Hepatitis C Completed NCT00001729 Phase 3 Ribavirin
14 Eight Week Primaquine Regimen for the Treatment of Vivax Malaria Completed NCT00158587 Phase 3 primaquine
15 Doppler or Amniocentesis to Predict Fetal Anemia Completed NCT00295516 Phase 3
16 Ofatumumab Added to Fludarabine-Cyclophosphamide vs Fludarabine-Cyclophosphamide Combination in Relapsed Subjects With Chronic Lymphocytic Leukemia Completed NCT00824265 Phase 3 OFC Infusion;FC infusion
17 Lapdap and Coartemether for Uncomplicated Malaria Completed NCT00118794 Phase 3 Chlorproguanil-dapsone (Lapdap);Lumefantrine-artemether (Coartemether )
18 Ofatumumab vs Physician's Choice in Subjects With Bulky Fludarabine-Refractory Chronic Lymphocytic Leukemia Completed NCT01313689 Phase 3 Ofatumumab;Physicians' Choice
19 A Study to Evaluate the Safety and Tolerability of Prophylactic Emicizumab in Hemophilia A Patients With Inhibitors Recruiting NCT03191799 Phase 3 Emicizumab
20 Eculizumab in Shiga-toxin Related Hemolytic and Uremic Syndrome Pediatric Patients - ECULISHU Recruiting NCT02205541 Phase 3 Eculizumab;Placebo
21 A Study to Evaluate the Efficacy and Safety of Belimumab Administered in Combination With Rituximab to Adult Subjects With Systemic Lupus Erythematosus (SLE) - BLISS-BELIEVE Recruiting NCT03312907 Phase 3 Belimumab;Rituximab;Rituximab-placebo;Standard therapy (Including Immunosuppressants);Standard therapy (Excluding Immunosuppressants);Steriod Taper
22 Ofatumumab Maintenance Treatment vs No Further Treatment in Relapsed CLL Responding to Induction Therapy Active, not recruiting NCT01039376 Phase 3
23 Ofatumumab + Chlorambucil vs Chlorambucil Monotherapy in Previously Untreated Patients With Chronic Lymphocytic Leukemia Active, not recruiting NCT00748189 Phase 3 chlorambucil, tablets;ofatumumab (GSK1841157) infusion
24 A Phase 3, Randomized, Controlled Study of Prophylactic and On-demand Treatment of cTTP With BAX 930 (rADAMTS13) Active, not recruiting NCT03393975 Phase 3
25 Efficacy and Safety of Levamisole Combined With Standard Prednisolone in Warm Antibody Autoimmune Hemolytic Anemia. Unknown status NCT01579110 Phase 2 levamisole;Prednisone
26 Safety and Efficacy of Levamisole Combined With Cyclosporine A in Patients With Classic Paroxysmal Nocturnal Hemoglobinuria Unknown status NCT01642979 Phase 2 Levamisole+cyclosporin A+Glucocorticoids;cyclosporin A+Glucocorticoids;Glucocorticoids
27 Safety and Efficacy of Levamisole Combined With Cyclosporine A in Patients With Subclinical Paroxysmal Nocturnal Hemoglobinuria and PNH in the Setting of Another Bone Marrow Failure Syndromes(PNH-2013) Unknown status NCT01760096 Phase 2 Levamisole+cyclosporin A+Glucocorticoids;cyclosporin A+Glucocorticoids;Glucocorticoids
28 Clinical Evaluation of Anti-CHIKV Hyperimmune Intravenous Immunoglobulins Unknown status NCT02230163 Phase 1, Phase 2
29 A Randomized Trial of LOVAZA in Pediatric Sickle Cell Disease (SCD) Unknown status NCT01202812 Phase 2
30 A Single-Arm Pilot Study With Low-Dose Rituximab Plus Standard Oral Prednisone In Idiopathic Autoimmune Hemolytic Anemia Completed NCT01345708 Phase 2 prednisone, low dose rituximab
31 Combination Chemotherapy and Rituximab in Treating Patients With Chronic Lymphocytic Leukemia (CLL) That Did Not Respond to Fludarabine, CLL With Autoimmune Haemolytic Anemia (AIHA) or Richter's Transformation (RT) Completed NCT00309881 Phase 2 cyclophosphamide;doxorubicin hydrochloride;prednisone;vincristine sulfate
32 High Dose Ribavirin in the Treatment of Chronic Hepatitis C Completed NCT00944684 Phase 2 High ribavirin dose;Standard ribavirin dose
33 Bendamustine and Rituximab Combination Therapy for Cold Agglutinin Disease Completed NCT02689986 Phase 2 Bendamustine, Rituximab
34 Study of Deferasirox Relative to Subcutaneous Deferoxamine in Sickle Cell Disease Patients Completed NCT00110617 Phase 2 Deferasirox (ICL670);Deferoxamine (DFO)
35 Clinical Trial to Study the Safety and Tolerability of Memantin Mepha® in Sickle Cell Disease Patients Completed NCT02615847 Phase 2 Memantinhydrochlorid
36 Therapy for Chronic Cold Agglutinin Disease Completed NCT00373594 Phase 2 Rituximab;Fludarabine
37 Vitamin E Supplement in Patients With Cirrhosis and Acanthocytosis Completed NCT01463735 Phase 2
38 Unrelated Hematopoietic Stem Cell Transplantation(HSCT) for Genetic Diseases of Blood Cells Completed NCT00730314 Phase 1, Phase 2
39 Glutamine Therapy for Hemolysis-Associated Pulmonary Hypertension Completed NCT01048905 Phase 2 L-Glutamine;L-Glutamine
40 Rituximab in Adult Acquired Idiopathic Thrombotic Thrombocytopenic Purpura Completed NCT00907751 Phase 2 rituximab
41 Bortezomib to Treat Significant Complication of HSCT Completed NCT01929980 Phase 2 Bortezomib
42 Phase II Study of High-Dose Cyclophosphamide in Patients With Severe Autoimmune Hematologic Disease Completed NCT00010387 Phase 2 cyclophosphamide;filgrastim
43 Efficacy of PegInterferon-Ribavirin-Boceprevir Therapy in Patients Infected With G1 HCV With Cirrhosis, Awaiting Liver Transplantation Completed NCT01463956 Phase 2 Boceprevir;Ribavirin
44 Ofatumumab Plus Bendamustine in Frontline and Relapsed Chronic Lymphocytic Leukaemia (CLL) Completed NCT01520922 Phase 2 Bendamustine
45 Efficacy and Safety of HyQvia (Immunoglobulin 10% With Recombinant Hyaluronidase) in Multifocal Motor Neuropathy (MMN) Completed NCT02556437 Phase 2 HyQvia;Subcuvia
46 Immunoglobulin for Necrotizing Soft Tissue Infections: a Randomised Controlled Trial Completed NCT02111161 Phase 2 IVIG (Privigen);Saline 0.9%
47 Evaluate Safety & Immunogenicity of a Pandemic Influenza Vaccine (GSK1562902A) in Children Completed NCT00502593 Phase 2
48 A Phase I/II, Open-label Study of Ofatumumab Added to Chlorambucil in Previously Untreated Japanese Patients With Chronic Lymphocytic Leukemia Completed NCT01563055 Phase 2 chlorambucil, tablets;ofatumumab (GSK1841157) infusion
49 Boceprevir in HIV-HCV Coinfected Patients Who Have Failed to a Previous Therapy With Peg-Interferon/Ribavirin Completed NCT01335529 Phase 2 Boceprevir, Peg-interferon alfa 2b and Ribavirin
50 A Safety and Efficacy Study of R935788 in the Treatment of Warm Antibody Autoimmune Hemolytic Anemia (AIHA) Recruiting NCT02612558 Phase 2 Fostamatinib 150 mg bid

Search NIH Clinical Center for Hemolytic Anemia

Inferred drug relations via UMLS 73 / NDF-RT 51 :


Cell-based therapeutics:


LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database
Read about Hemolytic Anemia cell therapies at LifeMap Discovery.

Cochrane evidence based reviews: anemia, hemolytic

Genetic Tests for Hemolytic Anemia

Genetic tests related to Hemolytic Anemia:

# Genetic test Affiliating Genes
1 Hemolytic Anemia 29

Anatomical Context for Hemolytic Anemia

MalaCards organs/tissues related to Hemolytic Anemia:

41
Bone, Heart, Bone Marrow, Liver, Spleen, Testes, Kidney

Publications for Hemolytic Anemia

Articles related to Hemolytic Anemia:

(show top 50) (show all 1562)
# Title Authors Year
1
Hepatosplenic T cell lymphoma: a unifying entity in a patient with hemolytic anemia, massive splenomegaly, and liver dysfunction. ( 29766398 )
2018
2
Increased number of tissue factor protein expressing thrombocytes in canine idiopathic immune mediated hemolytic anemia. ( 29695321 )
2018
3
Importance of the Average Glucose Level and Estimated Glycated Hemoglobin in a Diabetic Patient with Hereditary Hemolytic Anemia and Liver Cirrhosis. ( 29225250 )
2018
4
Cytomegalovirus reactivation can be a cause of DAT-negative hemolytic anemia in patients with chronic lymphocytic leukemia. ( 29911929 )
2018
5
Exacerbation of autoimmune hemolytic anemia induced by the first dose of programmed death-1 inhibitor pembrolizumab: a case report. ( 29340837 )
2018
6
Paraneoplastic Auto-immune Hemolytic Anemia: An Unusual Sequela of Enteric Duplication Cyst. ( 29277816 )
2018
7
Methylene blue-induced Heinz body hemolytic anemia in a premature neonate. ( 29314195 )
2018
8
Successful treatment of refractory autoimmune hemolytic anemia after allogeneic hematopoietic stem cell transplantation with bortezomib. ( 29345206 )
2018
9
Microangiopathic Hemolytic Anemia Following Three Different Species of Hump-Nosed Pit Viper (Genus: Hypnale) Envenoming in Sri Lanka. ( 29361387 )
2018
10
Hemolytic anemia due to native valve subacute endocarditis with<i>Actinomyces israelii</i>infection. ( 29445480 )
2018
11
A Case Report of Congenital Non-spherocytic Hemolytic Anemia in a Patient from India. ( 29904619 )
2018
12
Effects of therapeutic plasma exchange on serum immunoglobulin concentrations in a dog with refractory immune-mediated hemolytic anemia. ( 29641335 )
2018
13
Identification of a Novel Mutation in the SEC23B Gene Associated With Congenital Dyserythropoietic Anemia Type II Through the Use of Next-generation Sequencing Panel in an Undiagnosed Case of Nonimmune Hereditary Hemolytic Anemia. ( 29846281 )
2018
14
Mixed IgM cold and IgG warm autoimmune hemolytic anemia complicated by acral gangrene. ( 29683507 )
2018
15
Ominous comorbidities: Small ventricular septal defect and warm autoimmune hemolytic anemia. ( 29440848 )
2018
16
Life-threatening autoimmune warm hemolytic anemia following treatment for multiple sclerosis with alemtuzumab. ( 29359614 )
2018
17
Factors associated with immune hemolytic anemia after pediatric liver transplantation. ( 29885007 )
2018
18
Splenic myeloid metaplasia in warm autoimmune hemolytic anemia (wAIHA): a retrospective study. ( 29662860 )
2018
19
Molecular detection of Mycoplasma ovis in an outbreak of hemolytic anemia in sheep from Veracruz, Mexico. ( 29934796 )
2018
20
R Inguinal/R Scrotum Extramammary Paget's Disease with Diffuse Spine Metastasis Complicated by Microangiopathic Hemolytic Anemia. ( 29805822 )
2018
21
Spurious thrombocytosis in the setting of hemolytic anemia and microcytosis secondary to extensive burn injury. ( 29391327 )
2018
22
Simultaneous early-onset severe autoimmune hemolytic anemia and albuminuria during alemtuzumab treatment for multiple sclerosis. ( 29359617 )
2018
23
Eluate testing with monospecific antisera unmasks multiple immunoglobulin classes and identifies frequent IgA involvement in severe autoimmune hemolytic anemia. ( 29716828 )
2018
24
Whole-exome analysis to detect congenital hemolytic anemia mimicking congenital dyserythropoietic anemia. ( 29936674 )
2018
25
Features of peripheral CD8<sup>+</sup>CD57<sup>+</sup> lymphocytes in patients with autoimmune hemolytic anemia. ( 29845877 )
2018
26
Efficacy of D- red blood cell transfusion and rituximab therapy in autoimmune hemolytic anemia with anti-D and panreactive autoantibodies arising after hematopoietic stem cell transplant. ( 29664112 )
2018
27
Microangiopathic hemolytic anemia as initial presentation of recurrent colon cancer. ( 29963526 )
2018
28
Influence of immune-mediated hemolytic anemia on flow velocities in the portal vein and caudal vena cava measured by use of pulsed-wave Doppler ultrasonography in dogs. ( 29688778 )
2018
29
Durable responses in refractory autoimmune hemolytic anemia with alemtuzumab. ( 29334337 )
2018
30
Predictors of refractoriness to therapy and healthcare resource utilization in 378 patients with primary autoimmune hemolytic anemia from 8 Italian Reference Centers. ( 29981267 )
2018
31
Should Giant Cell Hepatitis With Autoimmune Hemolytic Anemia Be Considered a Pediatric Autoimmune Liver Disease? ( 29394216 )
2018
32
Case-control study of plasma mean platelet component concentration and survival analysis for dogs with immune-mediated hemolytic anemia. ( 29772969 )
2018
33
Parvovirus B19 infection associated with hemolytic anemia and cranial polyneuropathy. ( 28831691 )
2017
34
Diffuse Chorangiomatosis as a Cause of Cardiomegaly, Microangiopathic Hemolytic Anemia and Thrombocytopenia in a Newborn. ( 29227711 )
2017
35
Low-Dose Rituximab for Hemolytic Anemia Retreatment in a Patient With Systemic Lupus Erythematosus. ( 29232288 )
2017
36
An unusual association between hemophagocytic lymphohistiocytosis, mixed connective tissue disease, and autoimmune hemolytic anemia: A case report. ( 28700492 )
2017
37
Treatment of chronic lymphocytic leukemia/small lymphocytic lymphoma presenting simultaneously with acquired hemophilia and warm autoimmune hemolytic anemia. ( 28670081 )
2017
38
Tumor necrosis factor gene polymorphisms in adult patients with autoimmune hemolytic anemia. ( 28111935 )
2017
39
Congenital Hemolytic Anemia. ( 28189176 )
2017
40
An Atypical Presentation of Chronic Atrophic Gastritis: Hemolytic Anemia and Mesenteric Panniculitis. ( 28758037 )
2017
41
Successful treatment of tacrolimus-related pure red cell aplasia and autoimmune hemolytic anemia with rituximab in a pediatric cardiac transplant patient. ( 28598573 )
2017
42
Steroid-Refractory Autoimmune Hemolytic Anemia with Massive Splenomegaly. ( 28389309 )
2017
43
Warm autoimmune hemolytic anemia: experience from a single referral center in Mexico City. ( 28401101 )
2017
44
The first reported case of concurrent trimethoprim-sulfamethoxazole-induced immune hemolytic anemia and thrombocytopenia. ( 28905389 )
2017
45
Microangiopathic hemolytic anemia due to ADAMTS-13 loss in idiopathic systemic capillary leak syndrome: reply. ( 28182327 )
2017
46
Immune Thrombocytopenic Purpura and Hemolytic Anemia Secondary to Hepatitis A. ( 28875001 )
2017
47
Reliable assessment of the incidence of childhood autoimmune hemolytic anemia. ( 28748541 )
2017
48
Coinheritance of Hb Bristol-Alesha [I^67(E11)Vala89Met; HBB: c.202G&amp;gt;A] and the I+212 Patchwork Allele in a Brazilian Child with Severe Congenital Hemolytic Anemia. ( 28670945 )
2017
49
Autoimmune Hemolytic Anemia in Plasmodium vivax Malaria. ( 28290054 )
2017
50
Thyroid storm and warm autoimmune hemolytic anemia. ( 28870408 )
2017

Variations for Hemolytic Anemia

ClinVar genetic disease variations for Hemolytic Anemia:

6
(show top 50) (show all 132)
# Gene Variation Type Significance SNP ID Assembly Location
1 HBB NM_000518.4(HBB): c.127T> C (p.Phe43Leu) single nucleotide variant Pathogenic rs33924146 GRCh38 Chromosome 11, 5226765: 5226765
2 HBB NM_000518.4(HBB): c.127T> C (p.Phe43Leu) single nucleotide variant Pathogenic rs33924146 GRCh37 Chromosome 11, 5247995: 5247995
3 HBB NM_000518.4(HBB): c.127T> G (p.Phe43Val) single nucleotide variant Pathogenic rs33924146 GRCh37 Chromosome 11, 5247995: 5247995
4 HBB NM_000518.4(HBB): c.127T> G (p.Phe43Val) single nucleotide variant Pathogenic rs33924146 GRCh38 Chromosome 11, 5226765: 5226765
5 SLC4A1 NM_000342.3(SLC4A1): c.2712C> T (p.Tyr904=) single nucleotide variant Likely benign rs45519733 GRCh37 Chromosome 17, 42327850: 42327850
6 SLC4A1 NM_000342.3(SLC4A1): c.2712C> T (p.Tyr904=) single nucleotide variant Likely benign rs45519733 GRCh38 Chromosome 17, 44250482: 44250482
7 SLC4A1 NM_000342.3(SLC4A1): c.2688T> C (p.Asp896=) single nucleotide variant Benign/Likely benign rs45497993 GRCh37 Chromosome 17, 42327874: 42327874
8 SLC4A1 NM_000342.3(SLC4A1): c.2688T> C (p.Asp896=) single nucleotide variant Benign/Likely benign rs45497993 GRCh38 Chromosome 17, 44250506: 44250506
9 SLC4A1 NM_000342.3(SLC4A1): c.2584G> A (p.Val862Ile) single nucleotide variant Benign/Likely benign rs5026 GRCh37 Chromosome 17, 42328598: 42328598
10 SLC4A1 NM_000342.3(SLC4A1): c.2584G> A (p.Val862Ile) single nucleotide variant Benign/Likely benign rs5026 GRCh38 Chromosome 17, 44251230: 44251230
11 SLC4A1 NM_000342.3(SLC4A1): c.1953C> T (p.His651=) single nucleotide variant Likely benign rs5021 GRCh37 Chromosome 17, 42331968: 42331968
12 SLC4A1 NM_000342.3(SLC4A1): c.1953C> T (p.His651=) single nucleotide variant Likely benign rs5021 GRCh38 Chromosome 17, 44254600: 44254600
13 SLC4A1 NM_000342.3(SLC4A1): c.1770G> A (p.Lys590=) single nucleotide variant Likely benign rs35807245 GRCh38 Chromosome 17, 44255703: 44255703
14 SLC4A1 NM_000342.3(SLC4A1): c.1770G> A (p.Lys590=) single nucleotide variant Likely benign rs35807245 GRCh37 Chromosome 17, 42333071: 42333071
15 SLC4A1 NM_000342.3(SLC4A1): c.1323G> A (p.Leu441=) single nucleotide variant Benign/Likely benign rs5017 GRCh37 Chromosome 17, 42335135: 42335135
16 SLC4A1 NM_000342.3(SLC4A1): c.1323G> A (p.Leu441=) single nucleotide variant Benign/Likely benign rs5017 GRCh38 Chromosome 17, 44257767: 44257767
17 SLC4A1 NM_000342.3(SLC4A1): c.1249C> T (p.Leu417=) single nucleotide variant Likely benign rs5015 GRCh37 Chromosome 17, 42335387: 42335387
18 SLC4A1 NM_000342.3(SLC4A1): c.1249C> T (p.Leu417=) single nucleotide variant Likely benign rs5015 GRCh38 Chromosome 17, 44258019: 44258019
19 SLC4A1 NM_000342.3(SLC4A1): c.924G> A (p.Leu308=) single nucleotide variant Likely benign rs5013 GRCh37 Chromosome 17, 42335944: 42335944
20 SLC4A1 NM_000342.3(SLC4A1): c.924G> A (p.Leu308=) single nucleotide variant Likely benign rs5013 GRCh38 Chromosome 17, 44258576: 44258576
21 SLC4A1 NM_000342.3(SLC4A1): c.113A> C (p.Asp38Ala) single nucleotide variant Likely benign rs5035 GRCh37 Chromosome 17, 42338998: 42338998
22 SLC4A1 NM_000342.3(SLC4A1): c.113A> C (p.Asp38Ala) single nucleotide variant Likely benign rs5035 GRCh38 Chromosome 17, 44261630: 44261630
23 SLC4A1 NM_000342.3(SLC4A1): c.16-14G> A single nucleotide variant Likely benign rs145502796 GRCh38 Chromosome 17, 44262740: 44262740
24 SLC4A1 NM_000342.3(SLC4A1): c.16-14G> A single nucleotide variant Likely benign rs145502796 GRCh37 Chromosome 17, 42340108: 42340108
25 SLC4A1 NM_000342.3(SLC4A1): c.*1832G> A single nucleotide variant Uncertain significance rs886052988 GRCh37 Chromosome 17, 42325994: 42325994
26 SLC4A1 NM_000342.3(SLC4A1): c.*1832G> A single nucleotide variant Uncertain significance rs886052988 GRCh38 Chromosome 17, 44248626: 44248626
27 SLC4A1 NM_000342.3(SLC4A1): c.*1721G> A single nucleotide variant Likely benign rs62078947 GRCh37 Chromosome 17, 42326105: 42326105
28 SLC4A1 NM_000342.3(SLC4A1): c.*1721G> A single nucleotide variant Likely benign rs62078947 GRCh38 Chromosome 17, 44248737: 44248737
29 SLC4A1 NM_000342.3(SLC4A1): c.*1676A> G single nucleotide variant Uncertain significance rs745898810 GRCh37 Chromosome 17, 42326150: 42326150
30 SLC4A1 NM_000342.3(SLC4A1): c.*1676A> G single nucleotide variant Uncertain significance rs745898810 GRCh38 Chromosome 17, 44248782: 44248782
31 SLC4A1 NM_000342.3(SLC4A1): c.*1606_*1608dupAAA duplication Uncertain significance rs57466226 GRCh37 Chromosome 17, 42326218: 42326220
32 SLC4A1 NM_000342.3(SLC4A1): c.*1606_*1608dupAAA duplication Uncertain significance rs57466226 GRCh38 Chromosome 17, 44248850: 44248852
33 SLC4A1 NM_000342.3(SLC4A1): c.*1608delA deletion Uncertain significance rs886052989 GRCh37 Chromosome 17, 42326218: 42326218
34 SLC4A1 NM_000342.3(SLC4A1): c.*1608delA deletion Uncertain significance rs886052989 GRCh38 Chromosome 17, 44248850: 44248850
35 SLC4A1 NM_000342.3(SLC4A1): c.*1198A> T single nucleotide variant Uncertain significance rs886052992 GRCh38 Chromosome 17, 44249260: 44249260
36 SLC4A1 NM_000342.3(SLC4A1): c.*1198A> T single nucleotide variant Uncertain significance rs886052992 GRCh37 Chromosome 17, 42326628: 42326628
37 SLC4A1 NM_000342.3(SLC4A1): c.*897G> A single nucleotide variant Likely benign rs5030 GRCh38 Chromosome 17, 44249561: 44249561
38 SLC4A1 NM_000342.3(SLC4A1): c.*897G> A single nucleotide variant Likely benign rs5030 GRCh37 Chromosome 17, 42326929: 42326929
39 SLC4A1 NM_000342.3(SLC4A1): c.2210C> T (p.Ala737Val) single nucleotide variant Uncertain significance rs886052997 GRCh38 Chromosome 17, 44253219: 44253219
40 SLC4A1 NM_000342.3(SLC4A1): c.2210C> T (p.Ala737Val) single nucleotide variant Uncertain significance rs886052997 GRCh37 Chromosome 17, 42330587: 42330587
41 SLC4A1 NM_000342.3(SLC4A1): c.1637A> G (p.Asp546Gly) single nucleotide variant Uncertain significance rs886052998 GRCh38 Chromosome 17, 44255836: 44255836
42 SLC4A1 NM_000342.3(SLC4A1): c.1637A> G (p.Asp546Gly) single nucleotide variant Uncertain significance rs886052998 GRCh37 Chromosome 17, 42333204: 42333204
43 SLC4A1 NM_000342.3(SLC4A1): c.636A> G (p.Ser212=) single nucleotide variant Uncertain significance rs886053000 GRCh38 Chromosome 17, 44259555: 44259555
44 SLC4A1 NM_000342.3(SLC4A1): c.636A> G (p.Ser212=) single nucleotide variant Uncertain significance rs886053000 GRCh37 Chromosome 17, 42336923: 42336923
45 SLC4A1 NM_000342.3(SLC4A1): c.286C> T (p.Arg96Cys) single nucleotide variant Uncertain significance rs538778224 GRCh38 Chromosome 17, 44260698: 44260698
46 SLC4A1 NM_000342.3(SLC4A1): c.286C> T (p.Arg96Cys) single nucleotide variant Uncertain significance rs538778224 GRCh37 Chromosome 17, 42338066: 42338066
47 SLC4A1 NM_000342.3(SLC4A1): c.216G> T (p.Glu72Asp) single nucleotide variant Likely benign rs13306788 GRCh38 Chromosome 17, 44260768: 44260768
48 SLC4A1 NM_000342.3(SLC4A1): c.216G> T (p.Glu72Asp) single nucleotide variant Likely benign rs13306788 GRCh37 Chromosome 17, 42338136: 42338136
49 SLC4A1 NM_000342.3(SLC4A1): c.*1273delG deletion Uncertain significance rs768606768 GRCh38 Chromosome 17, 44249185: 44249185
50 SLC4A1 NM_000342.3(SLC4A1): c.*1273delG deletion Uncertain significance rs768606768 GRCh37 Chromosome 17, 42326553: 42326553

Expression for Hemolytic Anemia

Search GEO for disease gene expression data for Hemolytic Anemia.

Pathways for Hemolytic Anemia

Pathways related to Hemolytic Anemia according to GeneCards Suite gene sharing:

(show all 13)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.76 AK1 ALDOA G6PD GCLC GPI GSS
2
Show member pathways
12.63 ALDOA G6PD GPI HK1 PGK1 PKLR
3
Show member pathways
12.41 ALDOA GPI HK1 PGK1 PKLR
4 12.31 ALDOA G6PD HBB HK1
5
Show member pathways
11.76 ALDOA G6PD GPI HK1 PGK1 PKLR
6 11.69 ALDOA HK1 PGK1
7
Show member pathways
11.68 ALDOA HK1 PGK1 PKLR
8 11.47 ALDOA HK1 PGK1
9
Show member pathways
11.43 ALDOA G6PD GPI
10
Show member pathways
11 HBA2 HBB RHAG SLC4A1
11 10.61 PGK1 PKLR
12
Show member pathways
10.45 G6PD GPI HK1
13 10.13 G6PD GPI HK1 PGK1

GO Terms for Hemolytic Anemia

Cellular components related to Hemolytic Anemia according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular exosome GO:0070062 9.7 AK1 ALDOA CD59 G6PD GPI GSS
2 ficolin-1-rich granule lumen GO:1904813 9.58 ALDOA GPI HBB
3 cytosol GO:0005829 9.47 AK1 ALDOA ANK1 G6PD GCLC GPI
4 cortical cytoskeleton GO:0030863 9.43 EPB42 SLC4A1
5 endocytic vesicle lumen GO:0071682 9.37 HBA2 HBB
6 hemoglobin complex GO:0005833 9.32 HBA2 HBB
7 spectrin-associated cytoskeleton GO:0014731 9.26 ANK1 SPTB
8 haptoglobin-hemoglobin complex GO:0031838 9.16 HBA2 HBB

Biological processes related to Hemolytic Anemia according to GeneCards Suite gene sharing:

(show all 14)
# Name GO ID Score Top Affiliating Genes
1 carbohydrate metabolic process GO:0005975 9.76 G6PD GPI HK1 PKLR
2 hydrogen peroxide catabolic process GO:0042744 9.54 HBA2 HBB
3 gluconeogenesis GO:0006094 9.54 ALDOA GPI PGK1
4 regulation of blood vessel size GO:0050880 9.52 GCLC HBB
5 oxygen transport GO:0015671 9.51 HBA2 HBB
6 response to cadmium ion GO:0046686 9.5 GCLC GPI GSS
7 glutathione biosynthetic process GO:0006750 9.49 GCLC GSS
8 erythrocyte maturation GO:0043249 9.48 EPB42 G6PD
9 bicarbonate transport GO:0015701 9.46 HBA2 HBB RHAG SLC4A1
10 response to xenobiotic stimulus GO:0009410 9.43 GCLC GSS
11 glucose 6-phosphate metabolic process GO:0051156 9.43 G6PD GPI HK1
12 cellular ion homeostasis GO:0006873 9.4 RHAG SLC4A1
13 glycolytic process GO:0006096 9.35 ALDOA GPI HK1 PGK1 PKLR
14 canonical glycolysis GO:0061621 9.02 ALDOA GPI HK1 PGK1 PKLR

Molecular functions related to Hemolytic Anemia according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 ATP binding GO:0005524 9.98 AK1 EPB42 GCLC GSS HK1 PGK1
2 catalytic activity GO:0003824 9.71 ALDOA GCLC HK1 PKLR
3 structural constituent of cytoskeleton GO:0005200 9.54 ANK1 EPB42 SPTB
4 peroxidase activity GO:0004601 9.46 HBA2 HBB
5 magnesium ion binding GO:0000287 9.46 GCLC GSS NT5C3A PKLR
6 oxygen carrier activity GO:0005344 9.32 HBA2 HBB
7 glucose binding GO:0005536 9.26 G6PD HK1
8 haptoglobin binding GO:0031720 8.96 HBA2 HBB
9 ankyrin binding GO:0030506 8.8 RHAG SLC4A1 SPTB

Sources for Hemolytic Anemia

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....